Refine Search

Search Results -

Terms	Documents
L9 and night adj sight	1

Database: US Pre-Grant Publication Full-Text Database; US Patents Full-Text Database; US OCR Full-Text Database; EPO Abstracts Database; JPO Abstracts Database; Derwent World Patents Index; IBM Technical Disclosure Bulletins

Search: L11

Refine Search

Recall Text | Clear | Interrupt

Search History

DATE: Monday, September 27, 2004 Printable Copy Create Case

Set Name side by side	Query	Hit Count	Set Name result set
DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI; PLUR=YES; OP=OR			
L11	L9 and night adj sight	1	L11
L10	L9 and glare	5	L10
L9	L8 and @py>1975<=2002	55	L9
L8	L7 and eye	73	L8
L7	aceclidine	129	L7
L6	L5 and @py>1975<=2003	33	L6
L5	L4 and azelastine	43	L5
L4	antazoline	481	L4
L3	L2 and ophthalmic	38	L3
L2	L1 and pheniramine	98	L2
L1	ketotifen	960	L1

END OF SEARCH HISTORY

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1125zxf

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2		"Ask CAS" for self-help around the clock
NEWS 3	Jul 12	BEILSTEIN enhanced with new display and select options, resulting in a closer connection to BABS
NEWS 4	Jul 30	BEILSTEIN on STN workshop to be held August 24 in conjunction with the 228th ACS National Meeting
NEWS 5	AUG 02	IFIPAT/IFIUDB/IFICDB reloaded with new search and display fields
NEWS 6	AUG 02	CAplus and CA patent records enhanced with European and Japan Patent Office Classifications
NEWS 7	AUG 02	The Analysis Edition of STN Express with Discover! (Version 7.01 for Windows) now available
NEWS 8	AUG 04	Pricing for the Save Answers for SciFinder Wizard within STN Express with Discover! will change September 1, 2004
NEWS 9	AUG 27	BIOCOMMERCE: Changes and enhancements to content coverage
NEWS 10	AUG 27	BIOTECHABS/BIOTECHDS: Two new display fields added for legal status data from INPADOC
NEWS 11	SEP 01	INPADOC: New family current-awareness alert (SDI) available
NEWS 12	SEP 01	New pricing for the Save Answers for SciFinder Wizard within STN Express with Discover!
NEWS 13	SEP 01	New display format, HITSTR, available in WPIDS/WPINDEX/WPIX
NEWS 14	SEP 14	STN Patent Forum to be held October 13, 2004, in Iselin, NJ
NEWS 15	SEP 27	STANDARDS will no longer be available on STN
NEWS 16	SEP 27	SWETSCAN will no longer be available on STN

NEWS EXPRESS	JULY 30 CURRENT WINDOWS VERSION IS V7.01, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 11 AUGUST 2004
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

* * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 17:12:25 ON 27 SEP 2004

=> file ca,caplus,medline,biosis,wpids,drugu,uspatfull

```
COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                          ENTRY     SESSION
FULL ESTIMATED COST                                        1.26        1.26

FILE 'CA' ENTERED AT 17:16:09 ON 27 SEP 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'CAPLUS' ENTERED AT 17:16:09 ON 27 SEP 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'MEDLINE' ENTERED AT 17:16:09 ON 27 SEP 2004

FILE 'BIOSIS' ENTERED AT 17:16:09 ON 27 SEP 2004
Copyright (c) 2004 The Thomson Corporation.

FILE 'WPIDS' ENTERED AT 17:16:09 ON 27 SEP 2004
COPYRIGHT (C) 2004 THE THOMSON CORPORATION

FILE 'DRUGU' ENTERED AT 17:16:09 ON 27 SEP 2004
COPYRIGHT (C) 2004 THE THOMSON CORPORATION

FILE 'USPATFULL' ENTERED AT 17:16:09 ON 27 SEP 2004
CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

=> s ophthalmic (5a) aceclidine
L1           18 OPHTHALMIC (5A) ACECLIDINE

=> dup remove L1
PROCESSING COMPLETED FOR L1
L2           11 DUP REMOVE L1 (7 DUPLICATES REMOVED)

=> d L2 1-11 bib, ab

L2   ANSWER 1 OF 11  USPATFULL on STN
AN     2004:139468  USPATFULL
TI     Composition for treatment of night sight problems(halos, comas and
       glare) after refractive surgery, intra ocular lens implant after
       lensectomy or intraocular implant in phakic patients comprising
       aceclidine employed at low concentrations
IN     Randazzo, Alessandro, Milano, ITALY
PI     US 2004106644      A1   20040603
AI     US 2003-473740     A1   20031002 (10)
       WO 2002-EP3542          20020329
PRAI   IT 2001-MI708       20010403
DT     Utility
FS     APPLICATION
LREP   SUGHRUE MION, PLLC, 2100 PENNSYLVANIA AVENUE, N.W., SUITE 800,
       WASHINGTON, DC, 20037
CLMN   Number of Claims: 10
ECL    Exemplary Claim: 1
DRWN   3 Drawing Page(s)
LN.CNT 342
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB     After refractive surgery to reduce ametropy (i.e. myopia, astigmatism or
       hypermetropia) an average percentage of patients between 15.8% after PRK
       (Photo Refractive Keratectomy) and 33% after LASIK (Laser in situ
       Keratomileusis) shows a poor night sight due to the presence of halos,
       glare and coma. A comparable disorder is present in a percentage of
       patients that underwent lensectomy (cataract or refractive lensectomy)
       with intra ocular lens (IOL) implant and IOL implants in phakic patients
```

to reduce ametropy. Thanks to the effect on pupillary kinetics, diluted low concentrations (from 0.002% to 0.040%) of Aceclidine were surprisingly found to effectively reduce and/or eliminate night sight problems for about 6 hours.

L2 ANSWER 2 OF 11 CA COPYRIGHT 2004 ACS on STN DUPLICATE 1
AN 137:273249 CA
TI Composition for the treatment of night sight problems (halos, comas and glare) after refractive surgery, intra ocular lens implant after lensectomy or intraocular lens implant in phakic patients comprising aceclidine employed at low concentrations
IN Randazzo, Alessandro
PA Italy
SO PCT Int. Appl., 19 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002080915	A2	20021017	WO 2002-EP3542	20020329
	WO 2002080915	A3	20030103		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1377292	A2	20040107	EP 2002-727502	20020329
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	US 2004106644	A1	20040603	US 2003-473740	20031002
PRAI	IT 2001-MI708	A	20010403		
	WO 2002-EP3542	W	20020329		

AB Method is disclosed for the the treatment of night sight problems (halos, comas and glare) after ophthalmic surgery. After refractive surgery to reduce ametropy (i.e. myopia, astigmatism or hypermetropia) an average percentage of patients between 15.8% after PRK (Photo Refractive Keratectomy) and 33% after LASIK (Laser in situ Keratomileusis) shows a poor night sight due to the presence of halos, glare and coma. A comparable disorder is present in a percentage of patients that underwent lensectomy (cataract or refractive lensectomy) with intra ocular lens (IOL) implant and IOL implants in phakic patients to reduce ametropy. Thanks to the effect on pupillary kinetics, diluted low concns. (from 0.002% to 0.040%) of aceclidine were surprisingly found to effectively reduce and/or eliminate night sight problems for about 6 h.

L2 ANSWER 3 OF 11 CA COPYRIGHT 2004 ACS on STN DUPLICATE 2
AN 136:123671 CA
TI Ophthalmic formulation of a selective cyclooxygenase-2 inhibitory drug
IN Kararli, Tugrul T.; Bandyopadhyay, Rebanta; Singh, Satish K.; Hawley, Leslie C.
PA Pharmacia & Upjohn Company, USA
SO PCT Int. Appl., 71 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 4

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

PI WO 2002005815 A1 20020124 WO 2001-US22061 20010712
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
AU 2001075908 A5 20020130 AU 2001-75908 20010712
US 2002035264 A1 20020321 US 2001-904098 20010712
EP 1303271 A1 20030423 EP 2001-953462 20010712
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
JP 2004528267 T2 20040916 JP 2002-511747 20010712
PRAI US 2000-218101P P 20000713
US 2001-279285P P 20010328
US 2001-294838P P 20010531
US 2001-296388P P 20010606
WO 2001-US22061 W 20010712
OS MARPAT 136:123671
AB A pharmaceutical composition suitable for topical administration to an eye contains a selective COX-2 inhibitor or nanoparticles of a drug of low water solubility, at a concentration effective for the treatment and/or prophylaxis of a disorder in the eye, and 1 or more ophthalmically acceptable excipients that reduce rate of removal from the eye such that the composition has an effective residence time of 2-24 h. Also provided is a method of treating and/or preventing a disorder in an eye, the method comprising administering to the eye a composition of the invention. Thus, an ophthalmic nanoparticle suspension contained valdecoxib at 2.15 mg/g, 1.2% glycerin, 0.8% EDTA disodium salt, 4.0% Gelcarin GP-379NF, 0.21% SeaSpen PF and 0.82% Povidone.
RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 4 OF 11 CA COPYRIGHT 2004 ACS on STN DUPLICATE 3
AN 133:340234 CA
TI Ophthalmic compositions for the treatment of visual disorders characterized by a reduced contrast sensitivity
IN Boldrini, Enrico; Severino, Dario Ercole; Panelli, Giorgio; Bianchini, Pietro
PA Farmigea S.p.A., Italy
SO PCT Int. Appl., 28 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2000064425	A2	20001102	WO 2000-IT151	20000414
WO 2000064425	A3	20010412		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1173207	A2	20020123	EP 2000-927713	20000414
EP 1173207	B1	20021106		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO

AT 227135 E 20021115 AT 2000-927713 20000414

PRAI IT 1999-RM259 A 19990426

WO 2000-IT151 W 20000414

AB Disclosed are ophthalmic compns. able to reduce the impairments of the visual function (like halos, glare and reduction of the night and twilight vision) resulting from keratectomy operations carried out both with laser and by conventional techniques, from intraocular lens implantation (cataract surgery) and also resulting from various chronic pathologies affecting the anterior segment of the eyeball, such as the degenerations of the corneal tissue, which compns. contain one or more miotic agents, such as cholinomimetic active agents and cholinesterase inhibitors, in combination with one or more hypertonic agents, such as sulfacetamide and derivs. thereof, sodium chloride, glucose and glycerol. The miotic agents are selected from the group consisting of pilocarpine, carbachol, acetylcholine, aceclidine, physostigmine, and salts thereof.

L2 ANSWER 5 OF 11 CA COPYRIGHT 2004 ACS on STN DUPLICATE 4

AN 129:103734 CA

TI Bioavailability of timolol and aceclidine after ocular instillation in the rabbit

AU Matera, M. G.; Lampa, E.; Imperatore, A.; Berrino, L.; Russo, F.; Boldrini, E.; Rossi, F.

CS Institute of Pharmacology and Toxicology - Faculty of Medicine and Surgery, Second University of Naples, Naples, 80138, Italy

SO Research Communications in Molecular Pathology and Pharmacology (1998), 100(1), 35-42
CODEN: RCMPE6; ISSN: 1078-0297

PB PJD Publications Ltd.

DT Journal

LA English

AB The bioavailability of timolol and aceclidine after the ocular instillation of each drug (timolol 0.5% or aceclidine 2%) or both combined (timolol 0.5% + aceclidine 2%) has been evaluated in rabbits. 15 Male albino rabbits were treated by the instillation of timolol and aceclidine alone or combined in the conjunctival sac of the right eye. Timolol concns. in humor aqueous were assayed at 10 min, 30 min, 1 h, 2 h, 4 h and 6 h after instillation by HPLC. Aceclidine was assayed by a pharmacodynamic method: pupillary diameter at the following time intervals 0 (basal value), 1 min, 5 min, 30 min, 1 h, 2 h, 4 h, 6 h after treatment. The results demonstrated that no differences in timolol and aceclidine bioavailability were found between simple-drug prepns. and their combination.

RE.CNT 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 6 OF 11 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN

AN 1989:155577 BIOSIS

DN PREV198936077618; BR36:77618

TI GLAUCOMA TREATMENT IN 1988 DRUGS LASER OR SURGERY.

AU HAMARD H [Reprint author]

CS CENTRE HOSP NATL D'OPHTALMOL DES QUINZE-VINGTS, 28 RUE DE CHARENTON, 75571 PARIS, CEDEX 12

SO Semaine des Hopitaux, (1988) Vol. 64, No. 38-39, pp. 2522-2523.
Meeting Info.: CONTINUING EDUCATION COURSES OF BICHAT PITIE-SALPETRIERE, PARIS, FRANCE, SEPTEMBER 26-30, 1988. SEM HOP PARIS.
CODEN: SHPAAI. ISSN: 0037-1777.

DT Conference; (Meeting)

FS BR

LA FRENCH

ED Entered STN: 13 Mar 1989
Last Updated on STN: 13 Mar 1989

L2 ANSWER 7 OF 11 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN
AN 1985:57387 BIOSIS
DN PREV198528057387; BR28:57387
TI MEDICAL TREATMENT CHANCES IN CLOSED ANGLE GLAUCOMA.
AU REIBALDI A [Reprint author]; CANTATORE F; GUERRIERO S
CS ISTITUTO CLINICA OCULISTICA, UNIV BARI
SO Bollettino di Oculistica, (1984) Vol. 63, No. 7-8, pp. 669-674.
ISSN: 0006-677X.
DT Article
FS BR
LA ITALIAN

L2 ANSWER 8 OF 11 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN
AN 1983:178767 BIOSIS
DN PREV198375028767; BA75:28767
TI THE DUALISTIC EFFECT OF PILOCARPINE AT THE EYE.
AU PILZ J [Reprint author]; PILZ A
CS AUGENKLIN MED AKAD CARL GUSTAV CARUS, DDR-8019 DRESDEN, FETSCHERSTR 74
SO Folia Ophthalmologica (Leipzig), (1982) Vol. 7, No. 3, pp. 195-201.
CODEN: FOOPDZ. ISSN: 0323-4932.
DT Article
FS BA
LA GERMAN
AB The competitive dualism of pilocarpine observed on other animal muscles, which seems to oppose general clinical experiences, is confirmed on inner ocular muscles. Pilocarpine works as competitive antagonist of carbachol and aceclidine (glaucostat), when these occur in a concentration, the effect of which exceeds the intrinsic activity of pilocarpine. If the concentrations are below this value, pilocarpine works as a competitive agonist. The effect does not depend on the temporary consequence of application of the drugs. The main object of investigation was the isolated sphincter iridis of the cattle with an intrinsic activity of pilocarpine of 0.26, completed by experiments on the human sphincter and the ciliary muscle, in which the intrinsic activity of pilocarpine is higher.

L2 ANSWER 9 OF 11 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN
AN 1978:154518 BIOSIS
DN PREV197865041518; BA65:41518
TI ULTRASONOGRAPHIC STUDY OF THE EFFECT OF DIFFERENT MIOTICS ON THE EYE COMPONENTS.
AU FRANCOIS J [Reprint author]; GOES F
CS CLIN OPHTALMOL, AKAD ZIEKENHUIS, DE PINTELAAN 135, B-9000 GENT, BELG
SO Ophthalmologica, (1977) Vol. 175, No. 6, pp. 328-338.
CODEN: OPHTAD. ISSN: 0030-3755.
DT Article
FS BA
LA ENGLISH
AB The effect of topical instillations of carbachol 3%, pilocarpine 2%, aceclidine 2%, aceclidine 2%-adrenaline [epinephrine] 1% and of the Ocusert delivery system was determined and compared in 151 eyes' [human]. The depth of the anterior chamber, the thickness and the position of the lens, the length of the vitreous and the refraction were studied. Aceclidine has negligible side effects on the ocular components (maximal change of the anterior chamber 0.20 mm; maximal change of the lens thickness 0.14 mm; maximal myopisation: -1.5 δ. Carbachol has the strongest side effects (maximal change of the anterior chamber 0.80 mm; maximal change of the lens thickness 0.80 mm; maximal myopisation -11.50δ). Carbachol and pilocarpine may cause an important forward displacement of the lens with the risk of an angle-closure glaucoma in an eye with shallow anterior chamber.

L2 ANSWER 10 OF 11 CA COPYRIGHT 2004 ACS on STN DUPLICATE 5
AN 81:99141 CA
TI **Ophthalmic** bioavailability. I. Corneal penetration of **aceclidine** (3-acetoxyquinuclidine) into the rabbit eye using a perfusion technique
AU Brian, B.; Boltralik, J. J.; Thom, L.; Zeleznick, L. D.
CS Sci. Technol. Div., Alcon Lab., Inc., Fort Worth, TX, USA
SO Journal of Pharmaceutical Sciences (1974), 63(4), 633-5
CODEN: JPMSAE; ISSN: 0022-3549
DT Journal
LA English
AB A rapid, efficient, and sensitive method was developed for extraction and subsequent quantitation of aceclidine-HCl (3-acetoxyquinuclidine-HCl) (I) [6109-70-2] and 3-quinuclidinol-HCl [6238-13-7] from biol. fluid. After adjustment of pH and salt concentration, chloroform exts. of serum, urine, or aqueous fluid could be quantitated by gas-liquid chromatog. without derivative formation. The analytical procedure was used to determine the corneal absorption of I in the rabbit eye. I, a drug used topically in glaucoma treatment, entered the anterior chamber of the eye by penetration exclusively through the cornea. In expts. on conjunctival absorption, the amount of I found in the anterior chamber was <50 ng. The corneal absorption expts. gave cumulated absorption of 1-8.5 μg in 30 mins.

L2 ANSWER 11 OF 11 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN
AN 1982:75331 BIOSIS
DN PREV198223005323; BR23:5323
TI OCULAR BIOMETRY.
AU FRANCOIS J [Reprint author]
CS DEP OPHTHALMOL, UNIV GHENT, DE PINTELAAN, 135, B-9000 GHENT, BELG
SO Doc. Ophthalmol. Proc. Ser., pp. P135-164. THIJSSEN, J. M. AND A. M. VERBEEK (ED.). DOCUMENTA OPHTHALMOLOGICA PROCEEDINGS SERIES, VOL. 29. ULTRASONOGRAPHY IN OPHTHALMOLOGY; PROCEEDINGS OF THE 8TH SIDUO (SOCIETAS INTERNATIONALIS PRO DIAGNOSTICA ULTRASONICA IN OPHTHALMOLOGIA) CONGRESS, NIJMEGEN, NETHERLANDS. XIV+538P. DR W. JUNK BV PUBLISHERS: THE HAGUE, NETHERLANDS. BOSTON, MASS., USA (DIST. IN THE USA BY KLUWER BOSTON, INC.: HINGHAM, MASS.). ILLUS. 1981 (RECD. 1982).
Publisher: Series: Documenta Ophthalmologica Proceedings Series.
CODEN: DOPSBP. ISSN: 0303-6405. ISBN: 90-6193-724-8.
DT Book
Conference; (Meeting)
FS BR
LA ENGLISH

=> s aceclidine and glare
L3 11 ACECLIDINE AND GLARE

=> d l3 1-11 bib, ab

L3 ANSWER 1 OF 11 CA COPYRIGHT 2004 ACS on STN
AN 137:273249 CA
TI Composition for the treatment of night sight problems (halos, comas and **glare**) after refractive surgery, intra ocular lens implant after lensectomy or intraocular lens implant in phakic patients comprising **aceclidine** employed at low concentrations
IN Randazzo, Alessandro
PA Italy
SO PCT Int. Appl., 19 pp.
CODEN: PIXXD2
DT Patent
LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002080915	A2	20021017	WO 2002-EP3542	20020329
	WO 2002080915	A3	20030103		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1377292	A2	20040107	EP 2002-727502	20020329
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	US 2004106644	A1	20040603	US 2003-473740	20031002
PRAI	IT 2001-MI708	A	20010403		
	WO 2002-EP3542	W	20020329		

AB Method is disclosed for the the treatment of night sight problems (halos, comas and **glare**) after ophthalmic surgery. After refractive surgery to reduce ametropy (i.e. myopia, astigmatism or hypermetropia) an average percentage of patients between 15.8% after PRK (Photo Refractive Keratectomy) and 33% after LASIK (Laser in situ Keratomileusis) shows a poor night sight due to the presence of halos, **glare** and coma. A comparable disorder is present in a percentage of patients that underwent lensectomy (cataract or refractive lensectomy) with intra ocular lens (IOL) implant and IOL implants in phakic patients to reduce ametropy. Thanks to the effect on pupillary kinetics, diluted low concns. (from 0.002% to 0.040%) of **aceclidine** were surprisingly found to effectively reduce and/or eliminate night sight problems for about 6 h.

L3 ANSWER 2 OF 11 CA COPYRIGHT 2004 ACS on STN
AN 133:340234 CA
TI Ophthalmic compositions for the treatment of visual disorders characterized by a reduced contrast sensitivity
IN Boldrini, Enrico; Severino, Dario Ercole; Panelli, Giorgio; Bianchini, Pietro
PA Farmigea S.p.A., Italy
SO PCT Int. Appl., 28 pp.
CODEN: PIXXD2
DT Patent
LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000064425	A2	20001102	WO 2000-IT151	20000414
	WO 2000064425	A3	20010412		
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	EP 1173207	A2	20020123	EP 2000-927713	20000414
	EP 1173207	B1	20021106		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	AT 227135	E	20021115	AT 2000-927713	20000414

PRAI IT 1999-RM259 A 19990426
WO 2000-IT151 W 20000414

AB Disclosed are ophthalmic compns. able to reduce the impairments of the visual function (like halos, **glare** and reduction of the night and twilight vision) resulting from keratectomy operations carried out both with laser and by conventional techniques, from intraocular lens implantation (cataract surgery) and also resulting from various chronic pathologies affecting the anterior segment of the eyeball, such as the degenerations of the corneal tissue, which compns. contain one or more miotic agents, such as cholinomimetic active agents and cholinesterase inhibitors, in combination with one or more hypertonic agents, such as sulfacetamide and derivs. thereof, sodium chloride, glucose and glycerol. The miotic agents are selected from the group consisting of pilocarpine, carbachol, acetylcholine, **aceclidine**, physostigmine, and salts thereof.

L3 ANSWER 3 OF 11 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:793416 CAPLUS
DN 137:273249
TI Composition for the treatment of night sight problems (halos, comas and **glare**) after refractive surgery, intra ocular lens implant after lensectomy or intraocular lens implant in phakic patients comprising **aceclidine** employed at low concentrations
IN Randazzo, Alessandro
PA Italy
SO PCT Int. Appl., 19 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002080915	A2	20021017	WO 2002-EP3542	20020329
WO 2002080915	A3	20030103		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1377292	A2	20040107	EP 2002-727502	20020329
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 2004106644	A1	20040603	US 2003-473740	20031002

PRAI IT 2001-MI708 A 20010403
WO 2002-EP3542 W 20020329

AB Method is disclosed for the the treatment of night sight problems (halos, comas and **glare**) after ophthalmic surgery. After refractive surgery to reduce ametropy (i.e. myopia, astigmatism or hypermetropia) an average percentage of patients between 15.8% after PRK (Photo Refractive Keratectomy) and 33% after LASIK (Laser in situ Keratomileusis) shows a poor night sight due to the presence of halos, **glare** and coma. A comparable disorder is present in a percentage of patients that underwent lensectomy (cataract or refractive lensectomy) with intra ocular lens (IOL) implant and IOL implants in phakic patients to reduce ametropy. Thanks to the effect on pupillary kinetics, diluted low concns. (from 0.002% to 0.040%) of **aceclidine** were surprisingly found to effectively reduce and/or eliminate night sight problems for about 6 h.

L3 ANSWER 4 OF 11 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2000:772437 CAPLUS
DN 133:340234
TI Ophthalmic compositions for the treatment of visual disorders characterized by a reduced contrast sensitivity
IN Boldrini, Enrico; Severino, Dario Ercole; Panelli, Giorgio; Bianchini, Pietro
PA Farmigea S.p.A., Italy
SO PCT Int. Appl., 28 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000064425	A2	20001102	WO 2000-IT151	20000414
	WO 2000064425	A3	20010412		
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	EP 1173207	A2	20020123	EP 2000-927713	20000414
	EP 1173207	B1	20021106		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	AT 227135	E	20021115	AT 2000-927713	20000414
PRAI	IT 1999-RM259	A	19990426		
	WO 2000-IT151	W	20000414		

AB Disclosed are ophthalmic compns. able to reduce the impairments of the visual function (like halos, **glare** and reduction of the night and twilight vision) resulting from keratectomy operations carried out both with laser and by conventional techniques, from intraocular lens implantation (cataract surgery) and also resulting from various chronic pathologies affecting the anterior segment of the eyeball, such as the degenerations of the corneal tissue, which compns. contain one or more miotic agents, such as cholinomimetic active agents and cholinesterase inhibitors, in combination with one or more hypertonic agents, such as sulfacetamide and derivs. thereof, sodium chloride, glucose and glycerol. The miotic agents are selected from the group consisting of pilocarpine, carbachol, acetylcholine, **aceclidine**, physostigmine, and salts thereof.

L3 ANSWER 5 OF 11 WPIDS COPYRIGHT 2004 THE THOMSON CORP on STN
AN 2002-740978 [80] WPIDS
DNC C2002-209929
TI Use of **aceclidine** in the treatment of night sight problems in patients who have undergone refractive surgery or intraocular phakic lens implant or intraocular implant in aphakic patients.
DC B02
IN RANDAZZO, A
PA (RAND-I) RANDAZZO A
CYC 101
PI WO 2002080915 A2 20021017 (200280)* EN 19
RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ NL OA PT SD SE SL SZ TR TZ UG ZM ZW
W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

EP 1377292 A2 20040107 (200404) EN
R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT RO SE SI TR
AU 2002257735 A1 20021021 (200433)
US 2004106644 A1 20040603 (200436)

ADT WO 2002080915 A2 WO 2002-EP3542 20020329; EP 1377292 A2 EP 2002-727502 20020329, WO 2002-EP3542 20020329; AU 2002257735 A1 AU 2002-257735 20020329; US 2004106644 A1 WO 2002-EP3542 20020329, US 2003-473740 20031002

FDT EP 1377292 A2 Based on WO 2002080915; AU 2002257735 A1 Based on WO 2002080915

PRAI IT 2001-MI708 20010403

AB WO 200280915 A UPAB: 20021212

NOVELTY - Use of **aceclidine** (I) or one of its derivatives in the manufacture of a composition for the treatment of night sight problems (i.e. halos, coma and **glare**) in patients who have undergone refractive surgery or intraocular phakic lens implant or intraocular implant in aphakic patients, is new.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for:

(1) Pharmaceutical composition for the treatment of night sight problems (i.e. halos, coma and **glare**) in patients who have undergone refractive surgery or intraocular phakic lens implant or intraocular implant in aphakic patients, comprising (I) and a carrier; and

(2) Method of treating night sight problems (i.e. halos, coma and **glare**) in patients who have undergone refractive surgery or intraocular phakic lens implant or intraocular implant in aphakic patients, by topical administration of (I) in an ophthalmic composition.

ACTIVITY - Ophthalmic.

In a double-masked randomized clinical trial with 14 patients (27 eyes), it was found that 18 out of 19 eyes treated with **aceclidine** ophthalmic compositions versus 2 out of 8 treated with placebo showed an improvement in night vision problems (95 vs 25%). The efficacy was 6 hours with onset after 15-20 minutes following instillation. Side effects were modest and transient.

MECHANISM OF ACTION - None given.

USE - (I) is used in the treatment of night sight problems (i.e. halos, coma and **glare**) in patients who have undergone refractive surgery or intraocular phakic lens implant or intraocular implant in aphakic patients.

ADVANTAGE - (I) solves the problem of light ray diffraction and aberration during the night hours. Administration of an ophthalmic composition containing (I) and in very low concentrations may effectively reduce the pupillary diameter for a period of up to 6 hours. (I) has high selectivity compared to other parasympathomimetic drugs, addressing the effective reduction/prevention of halos, coma and glares in patients who had refractive surgery, where no side effects were detectable.

Dwg.0/3

L3 ANSWER 6 OF 11 USPATFULL on STN

AN 2004:139468 USPATFULL

TI Composition for treatment of night sight problems(halos, comas and **glare**) after refractive surgery, intra ocular lens implant after lensectomy or intraocular implant in phakic patients comprising **aceclidine** employed at low concentrations

IN Randazzo, Alessandro, Milano, ITALY

PI US 2004106644 A1 20040603

AI US 2003-473740 A1 20031002 (10)
WO 2002-EP3542 20020329

PRAI IT 2001-MI708 20010403

DT Utility

FS APPLICATION

LREP SUGHRUE MION, PLLC, 2100 PENNSYLVANIA AVENUE, N.W., SUITE 800, WASHINGTON, DC, 20037

CLMN Number of Claims: 10

ECL Exemplary Claim: 1
DRWN 3 Drawing Page(s)
LN.CNT 342
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB After refractive surgery to reduce ametropy (i.e. myopia, astigmatism or hypermetropia) an average percentage of patients between 15.8% after PRK (Photo Refractive Keratectomy) and 33% after LASIK (Laser in situ Keratomileusis) shows a poor night sight due to the presence of halos, **glare** and coma. A comparable disorder is present in a percentage of patients that underwent lensectomy (cataract or refractive lensectomy) with intra ocular lens (IOL) implant and IOL implants in phakic patients to reduce ametropy. Thanks to the effect on pupillary kinetics, diluted low concentrations (from 0.002% to 0.040%) of **Aceclidine** were surprisingly found to effectively reduce and/or eliminate night sight problems for about 6 hours.

L3 ANSWER 7 OF 11 USPATFULL on STN
AN 2003:206917 USPATFULL
TI Medical uses of in situ formed gels
IN Viegas, Tacey X., Birmingham, AL, UNITED STATES
Reeve, Lorraine E., Dexter, MI, UNITED STATES
Henry, Raymond L., St. Clair Shores, MI, UNITED STATES
PI US 2003143274 A1 20030731
AI US 2002-234922 A1 20020904 (10)
RLI Continuation of Ser. No. US 2000-628227, filed on 28 Jul 2000, PENDING Continuation of Ser. No. US 1999-330618, filed on 11 Jun 1999, GRANTED, Pat. No. US 6136334 Continuation of Ser. No. US 1996-773755, filed on 23 Dec 1996, GRANTED, Pat. No. US 5958443 Continuation of Ser. No. US 1993-174101, filed on 28 Dec 1993, GRANTED, Pat. No. US 5587175 Division of Ser. No. US 1991-785305, filed on 30 Oct 1991, GRANTED, Pat. No. US 5318780
DT Utility
FS APPLICATION
LREP Pillsbury Winthrop, LLP, Suite 200, 11682 El Camino Real, San Diego, CA, 92130
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1147
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Balanced pH, hyperosmotic, hypoosmotic, or isoosmotic gels are ideal vehicles for drug delivery. They are especially suited for topical body cavity or injection application of drugs or diagnostic agents; for drug or diagnostic agent delivery to the eye of a mammal; as protective corneal shields; or as ablatable corneal masks useful in laser reprofiling of the cornea. The compositions without the addition of a drug or diagnostic agent are useful as medical devices, for instance, in separating surgically or otherwise injured tissue as a means of preventing adhesions.

L3 ANSWER 8 OF 11 USPATFULL on STN
AN 2000:141902 USPATFULL
TI Medical uses of in situ formed gels
IN Viegas, Tacey X., Birmingham, AL, United States
Reeve, Lorraine E., Dexter, MI, United States
Henry, Raymond L., St. Clair Shores, MI, United States
PA MDV Technologies, Inc., San Diego, CA, United States (U.S. corporation)
PI US 6136334 20001024
AI US 1999-330618 19990611 (9)
RLI Continuation of Ser. No. US 1996-773755, filed on 23 Dec 1996, now patented, Pat. No. US 5958443 which is a continuation of Ser. No. US 1993-174101, filed on 28 Dec 1993, now abandoned which is a continuation of Ser. No. US 1991-785305, filed on 30 Oct 1991, now patented, Pat. No. US 5318780

DT Utility
FS Granted
EXNAM Primary Examiner: Azpuru, Carlos
LREP Pillsbury Madison & Sutro, LLPW. Patrick BengtssonNan Wu
CLMN Number of Claims: 8
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1137
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Balanced pH, hyperosmotic, hypoosmotic, or isoosmotic gels are ideal vehicles for drug delivery. They are especially suited for topical body cavity or injection application of drugs or diagnostic agents; for drug or diagnostic agent delivery to the eye of a mammal; as protective corneal shields; or as ablatable corneal masks useful in laser reprofiling of the cornea. The compositions without the addition of a drug or diagnostic agent are useful as medical devices, for instance, in separating surgically or otherwise injured tissue as a means of preventing adhesions.

L3 ANSWER 9 OF 11 USPATFULL on STN
AN 1999:117015 USPATFULL
TI Medical uses of in situ formed gels
IN Viegas, Tacey X., Canton, MI, United States
Reeve, Lorraine E., Dexter, MI, United States
Henry, Raymond L., Grosse Pointe Woods, MI, United States
PA MDV Technologies, Inc., San Diego, CA, United States (U.S. corporation)
PI US 5958443 19990928
AI US 1996-773755 19961223 (8)
RLI Continuation of Ser. No. US 1993-174101, filed on 28 Dec 1993, now patented, Pat. No. US 5587175 which is a continuation of Ser. No. US 1991-785305, filed on 30 Oct 1991, now patented, Pat. No. US 5318780
DT Utility
FS Granted
EXNAM Primary Examiner: Azpuru, Carlos A.
LREP Pillsbury Madison & Sutro LLP
CLMN Number of Claims: 39
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1248
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Balanced pH, hyperosmotic, hypoosmotic, or isoosmotic gels are ideal vehicles for drug delivery. They are especially suited for topical body cavity or injection application of drugs or diagnostic agents; for drug or diagnostic agent delivery to the eye of a mammal; as protective corneal shields; or as ablatable corneal masks useful in laser reprofiling of the cornea. The compositions without the addition of a drug or diagnostic agent are useful as medical devices, for instance, in separating surgically or otherwise injured tissue as a means of preventing adhesions.

L3 ANSWER 10 OF 11 USPATFULL on STN
AN 96:118391 USPATFULL
TI Medical uses of in situ formed gels
IN Viegas, Tacey X., Canton, MI, United States
Reeve, Lorraine E., Dexter, MI, United States
Henry, Raymond L., Grosse Pointe Woods, MI, United States
PA MDV Technologies, Inc., Dearborn, MI, United States (U.S. corporation)
PI US 5587175 19961224
AI US 1993-174101 19931228 (8)
RLI Division of Ser. No. US 1991-785305, filed on 30 Oct 1991, now patented, Pat. No. US 5318780
DT Utility
FS Granted
EXNAM Primary Examiner: Azpuru, Carlos

LREP Banner & Witcoff, Ltd.
CLMN Number of Claims: 11
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1104
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Balanced pH, hyperosmotic, hypoosmotic, or isoosmotic gels are ideal vehicles for drug delivery. They are especially suited for topical body cavity or injection application of drugs or diagnostic agents; for drug or diagnostic agent delivery to the eye of a mammal; as protective corneal shields; or as ablatable corneal masks useful in laser reprofiling of the cornea. The compositions without the addition of a drug or diagnostic agent are useful as medical devices, for instance, in separating surgically or otherwise injured tissue as a means of preventing adhesions.

L3 ANSWER 11 OF 11 USPATFULL on STN
AN 94:48963 USPATFULL
TI Medical uses of in situ formed gels
IN Viegas, Tacey X., Canton, MI, United States
Reeve, Lorraine E., Dexter, MI, United States
Henry, Raymond L., Grosse Pointe Woods, MI, United States
PA Mediventures Inc., Dearborn, MI, United States (U.S. corporation)
PI US 5318780 19940607
AI US 1991-785305 19911030 (7)
DCD 20081210
DT Utility
FS Granted
EXNAM Primary Examiner: Page, Thurman K.; Assistant Examiner: Azpuru, Carlos
LREP Dykema Gossett
CLMN Number of Claims: 9
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1057
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Balanced pH, hyperosmotic, hypoosmotic, or isoosmotic gels are ideal vehicles for drug delivery. They are especially suited for topical body cavity or injection application of drugs or diagnostic agents; for drug or diagnostic agent delivery to the eye of a mammal; as protective corneal shields; or as ablatable corneal masks useful in laser reprofiling of the cornea. The compositions without the addition of a drug or diagnostic agent are useful as medical devices, for instance, in separating surgically or otherwise injured tissue as a means of preventing adhesions.